Funding supports the distribution of Artera’s flagship test in prostate cancer, as well as further test development across cancers SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal ...

Spotlight Medical, a Paris-based oncology diagnostics company, today announced that myStage Dx has received CE marking under the European Union In Vitro Diagnostic Medical Devices Regulation (IVDR, ...

Myriad Genetics (MYGN) announced that its Prolaris prostate cancer prognostic test continues to be classified by the National Comprehensive Cancer Network, NCCN, as an ‘Advanced Tool’ in the fight ...

Telo Genomics Corp (TSE:TELO) has released an update. Telo Genomics Corp has revealed promising results for its TeloViewSMM prognostic test, which outperformed existing models in identifying high and ...

Toronto, Ontario--(Newsfile Corp. - October 22, 2024) - Telo Genomics Corp. (TELO:CA) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology ...

NEW YORK--(BUSINESS WIRE)--Ataraxis AI, a frontier artificial intelligence (AI) research lab developing AI-powered tools for oncology, today announced Ataraxis™ Breast CTX, a new predictive capability ...

The hazard ratio (HR) for the primary endpoint was (3.84, p = 0.0009) in the first month The Prolocor pFCG™ test has the potential to help providers reduce 30-day readmission rates for Acute MI, an ...

Managing the invisible: Treatment approaches after pathological complete response (pCR) to neoadjuvant chemotherapy in oral cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I ...

Mumbai: A cancer prognostic test, developed by the family members of the late joint commissioner of police Himanshu Roy who ...